Tegaserod


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Chronic idiopathic constipation; Constipation-predominant irritable bowel syndrome 6 mg twice daily for 4-6 wk, continued for another 4-6 wk in responsive patients.
Dosage Details
Oral
Chronic idiopathic constipation, Constipation-predominant irritable bowel syndrome
Adult: 6 mg taken bid for 4-6 wk continued for another 4-6 wk in responsive patients.
Renal Impairment
Severe impairment: Not recommended.
Hepatic Impairment
Moderate to severe impairment: Not recommended.
Administration
Should be taken on an empty stomach.
Contraindications
Severe renal or moderate to severe hepatic impairment; history of bowel obstruction or symptomatic gallbladder disease; suspected sphincter of Oddi dysfunction or abdominal adhesions; known hypersensitivity. Patients currently experiencing or who frequently experience diarrhoea. Lactation.
Special Precautions
Discontinue immediately if rectal bleeding, bloody diarrhoea, new or sudden worsening of abdominal pain occurs. Mild hepatic impairment; child <18 yr; pregnancy.
Adverse Reactions
Diarrhoea, abdominal pain, nausea, flatulence, headache, dizziness, migraine, leg or back pain, arthropathy, insomnia, hypotension, arrhythmia, ischaemic colitis.
Potentially Fatal: MI, stroke.
Drug Interactions
Potentially Fatal: Reduction in peak plasma conc of digoxin.
Food Interaction
Food reduces bioavailability by 40-65% and Cmax 20-40%. Tmax is prolonged from approx 1-2 hrs.
Action
Description: Tegaserod, is a prokinetic with partial agonistic activity at 5HT4. Activation of these receptors stimulate peristaltic reflex and intestinal secretion as well as inhibit visceral sensitivity.
Pharmacokinetics:
Absorption: Bioavailability: 10%. Peak plasma concentrations after 1 hr.
Distribution: Protein-binding: 98% primarily to α-acid glycoprotein. Widely distributed into tissues.
Metabolism: Extensively hepatic by oxidation, conjugation and glucuronidation; hydrolysis in the stomach.
Excretion: Faeces (as unchanged drug), urine (as metabolites). Terminal half life: 11hr.
Storage
Store at 25°C.
Disclaimer: This information is independently developed by MIMS based on Tegaserod from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in